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Asymptomatic human visceral leishmaniasis was identified
in Israel by using an enzyme-linked immunosorbent assay.
Positive serum samples were more prevalent in visceral leish-
maniasis–endemic (2.97%) compared to nonendemic (1.01%)
regions (p=0.021). Parasite exposure was higher than expect-
ed, despite the small number of clinical cases, suggesting fac-
tors other than infection per se influence clinical outcome.
H
uman visceral leishmaniasis (HVL), caused by the
Leishmania donovani complex, is lethal if not promptly
diagnosed and treated (1). Yet in the Mediterranean and Middle
East, only a small percentage of infections progress to clinical
disease (2,3). HVL in this region is primarily a disease of
young children; however, its epidemiology is changing. In
southern Europe, 50% of new cases are in adults coinfected
with HIV (4). 
HVL is endemic in northern Israel; 68 cases, mostly from
Arab villages, were documented from 1960 to 1989 (5). Since
1993, a drastic reduction in the disease was observed, despite
the identification of nine active sites of canine visceral leishma-
niasis (VL) in this region (G. Baneth and C. L. Jaffe, unpub.
data). Recent studies have identified an emerging focus of
human and canine disease near major population centers in
central Israel and the Palestinian Authority (6,7). In this study,
HVL seroprevalence in northern Israel was compared with that
in a region free of clinical disease.
The Study
Prevalence of asymptomatic disease was examined by ran-
dom cluster sampling of serum samples from 12 sites (494
serum samples) in a region presumed to be non-HVL-endemic
(i.e., HVL has not been reported) and 11 sites (2,086 serum
samples) in the HVL-endemic northern region, where the dis-
ease was previously reported in 8 of 11 sites (Figure). Coded
samples were analyzed blindly by enzyme-linked immunosor-
bent assay on L. donovani antigen for anti-leishmanial antibod-
ies (5). Each plate was read when the positive control serum
(1/1,000 dilution) absorbance λ405 nm = 1.0-1.2. Most serum sam-
ples were from women ages 18-45. The mean ages for patients
in the non-disease-endemic and HVL-endemic regions were 36
and 30 years, respectively (range <1 to >75). No symptomatic
HVL was diagnosed during the study.
The mean absorbance for serum samples from HVL-endem-
ic areas (0.0956; 95% confidence interval [CI] 0.0926 to
0.0986) was significantly higher (p=0.0001; unpaired t test
with Welch's correction) than that for serum samples from non-
disease-endemic areas (0.0832; 95% CI 0.0779 to 0.0885). The
percentage of positive samples (mean of the non-HVL-endem-
ic population + 3 standard deviations) was significantly higher
(p=0.021, chi-square test) for the endemic, 2.97% (n=62) than
for the non-HVL-endemic region, 1.01% (n=5). Age was
directly standardized by examining the percent positive serum
samples in children ≤14 years of age, who are most likely to
have clinical HVL, and older study participants (>14 years).
The standardized prevalence ratio of positive serum samples in
the HVL-endemic to non-HVL-endemic regions was 2.90.
Western blotting was used to confirm asymptomatic VL (8).
Strong reactions were observed to 14- and/or 18-kDa antigens
with all positive samples; weak or no bands were observed with
negative samples.
The percentage of positive serum samples for each site is
shown (Figure). In the non-HVL-endemic region, most serum
samples collected (64.6%) came from Atlit (Jewish, n=146)
and Isfiya (Arab, n=173). The remaining serum samples
(n=175) originated from 10 sites, with a maximum of 39 sam-
ples per site. Only 1.1% of these samples (2/175) were positive,
a value similar to that found for the larger towns of Atlit and
Isfiya (p=1.0, Fisher exact test). Essentially no difference in the
percentage of positive serum samples (p=1.0, Fisher exact test)
was found between non-leishmaniasis-endemic Arab (Isfiya,
1.2%) and Jewish (Atlit, 0.7%) towns, even though residents of
Isfiya are more likely to visit villages where the disease occurs.
Large numbers of samples (>140/site) were collected from
9 of 11 HLV-endemic sites. The percentage of positive samples
from Arab areas (3.1%) was not significantly higher (p=0.46,
chi-square test) than for samples from Jewish areas (1.8%),
even though most HVL case-patients in this region are from
Arab villages. However, the percentage of positive serum spec-
imens in 7 of 11 HVL-endemic sites was three- to six-fold the
average percentage found in the non-HVL-endemic region. The
number and percentage of positive HVL-endemic serum sam-
ples during the second year were almost twice (3.9%; p=0.038,
unpaired t test) the figures observed for the first year (2.2%).
The opposite trend was found in the non-HVL-endemic region,
where the number and percentage of positive samples
decreased from 1.9% to 0.3% (p=0.044) in the first and second
year, respectively. Nine of the 11 HLV-endemic sites showed
increases in the percentage of positive serum samples during
the second year.
During the 1960s, 45 cases of VL were diagnosed in west-
ern Galilee; more than half were from eight sites, all Arab vil-
lages, included in this study (5). Since then, the incidence of
HVL in northern Israel has decreased: only three cases have
been diagnosed in the last 7 years. This finding is not due to the
absence of parasite transmission, since canine VL remains
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is decreasing in northern Israel, the disease has emerged in cen-
tral Israel, where numerous dogs and seven persons have been
diagnosed with VL since the index HVL case in 1994 (6).
Villages in both regions are rural, and stray dogs and jackals are
frequently observed. The conditions contributing to the
changes in disease epidemiology in Israel are unknown but are
likely multifactorial. Studies in Brazil on risk factors associat-
ed with asymptomatic infection concluded that infection is
associated with age (≥2 years), location of dwellings, and pres-
ence of relatives with acute VL. Malnutrition was not associat-
ed with infection (9). Ahigher standard of living and health was
also postulated to be involved in decreased VL incidence over
the past 10 years (10). During the last decade, improvements in
the standard of living, health care, and infrastructure of Arab
villages in Israel have taken place. Though data are not avail-
able for most study sites, the percentage of seropositive persons
in Yirka, for example, decreased from 10% in 1989 (5) to 1.5%
in the current study (1994-1996), suggesting that exposure to
parasites in Yirka has decreased during the last decade.
The percentage of seropositive people is significantly
greater in the HVL-endemic northern than the non-HVL-
endemic coastal and Carmel Mountain regions. The presence of
positive samples in the non-HVL-endemic region suggests that
parasite transmission occurs, even though HVL has not been
reported. Since people from this region frequently travel to
northern Israel, we cannot exclude the possibility that they
were infected there. Although the incidence of the disease is
lower in Israel than in other HVL-endemic regions, our results
suggest that cumulative exposure to the parasite and asympto-
matic infection in Israel are more frequent than otherwise pre-
dicted, based on the yearly incidence of VL. These data will be
important in understanding the spread of human and canine dis-
ease into new regions, transmission by blood transfusion, and
the potential risk for VL/HIV coinfection. 
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Figure. Percentage of positive serum samples and average mid-day
temperatures, visceral leishmaniasis study sites, northern Israel 
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